Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
| Autor: | Patel, Kishan K. 1, Isufi, Iris 1, Kothari, Shalin 1, Davidoff, Amy J. 2, 3, Gross, Cary P. 2, Huntington, Scott F. 1, 1, 2 |
|---|---|
| Zdroj: | In Blood 22 October 2020 136(17):1946-1955 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|